CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 510 enrolled
Drug / intervention
Trabectedindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02793050
NCT02793050N/ACompleted

Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)

Italian Sarcoma Group·observational·Posted Jun 8, 2016·Updated May 10, 2019

In Brief

An observational study evaluating Trabectedin for Sarcoma, Soft Tissue. Completed, enrolled 510 participants across 26 sites.

Detailed Summary

This is an independent, observational, retrospective post marketing study on the use of trabectedin in a clinical setting. A data collection on the clinical use of the drug will help to improve knowledge and might contribute to optimize the clinical use of the drug.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 8, 2016
Enrollment StartJun 15, 2016
Primary CompletionOct 2, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.1 years ago

Interventions

Trabectedindrug

Collection of data on the clinical use of Trabectedin